Revive Therapeutics (XCNQ:RVV) Change In Receivables : C$0.01 Mil (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Revive Therapeutics Change In Receivables?

Revive Therapeutics's change in receivables for the quarter that ended in Sep. 2024 was C$-0.01 Mil. It means Revive Therapeutics's Accounts Receivable increased by C$0.01 Mil from Jun. 2024 to Sep. 2024 .

Revive Therapeutics's change in receivables for the fiscal year that ended in Jun. 2024 was C$0.01 Mil. It means Revive Therapeutics's Accounts Receivable declined by C$0.01 Mil from Jun. 2023 to Jun. 2024 .

Revive Therapeutics's Accounts Receivable for the quarter that ended in Sep. 2024 was C$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Revive Therapeutics's liquidation value for the three months ended in Sep. 2024 was C$-3.02 Mil.

Revive Therapeutics Change In Receivables Historical Data

The historical data trend for Revive Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revive Therapeutics Change In Receivables Chart

Revive Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Receivables

Get a 7-Day Free Trial

-0.10

0.07

-0.05

0.06

0.01

Revive Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															-	-0.03	-0.01	0.06	-0.01

Revive Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.01 Mil.

Revive Therapeutics (XCNQ:RVV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Revive Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Revive Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Revive Therapeutics's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.273	-	3.289	+	0.75 * 0	+	0.5 * 0
=	-3.02

Revive Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Revive Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Revive Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Revive Therapeutics Ltd (XCNQ:RVV) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

RVVTF:USA 31R:Germany

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1

Website

https://www.revivethera.com

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.

Executives

Michael Frank	Director, Senior Officer
Derrick Alexander Welsh	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)

Revive Therapeutics Headlines

No Headlines